WuXi and Inhibrx agree to work together on biologics manufacturing
Shanghai-based WuXi Biologics (HK: 2269) has inked a deal with Inhibrx, a Californian startup which is developing a pipeline of novel protein-based therapeutics.
Inhibrx will exclusively use WuXi Biologics for GMP manufacturing of its human biologic therapeutics for all projects initiated within the next three years for which Inhibrx plans to first initiate clinical trials outside of China.
Over the last two years, WuXi and Inhibrx have worked together on GMP manufacturing of one of the firm’s biologics, initiating a Phase I clinical study, as well as four biologics for which investigational new drug (IND) regulatory filings are expected to be forthcoming.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
Free
7 day trial access
- All the news that moves the needle in pharma and biotech
- Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
- Receive The Pharma Letter daily news bulletin, free forever.
Become a subscriber
£820
Or £77 per month
- Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
- Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
- Daily roundup of key events in pharma and biotech.
- Monthly in-depth briefings on Boardroom appointments and M&A news.
- Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
More on this story...
Today's issue
Company Spotlight
More Features in Biotechnology
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze